PharmaVoice
AUGUST 16, 2022
Nasal vaccines under development by Codagenix, Xanadu Bio and others have the potential to finally help reduce virus transmission and breakthrough infections.
PhRMA
AUGUST 16, 2022
Innovative biopharmaceutical research companies have been dedicated to fighting COVID-19 for over two years. Since the start of the pandemic, America’s biopharmaceutical companies have worked around the clock to research, develop and manufacture treatments and vaccines to fight COVID-19. We’ve made unprecedented progress in a short time thanks to decades of experience having produced over 14 billion vaccines globally to date.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
PharmaVoice
AUGUST 16, 2022
In balancing two roles — Lexitas CEO and practicing physician — George Magrath brings a patient-first perspective to developing and advancing eye treatments.
Pharmacy Times
AUGUST 16, 2022
Insurer and pharmacy benefit manager policies used to cut the cost of drugs could be so time consuming that they could put newly diagnosed atrial fibrillation patients at risk of stroke.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Outsourcing Pharma
AUGUST 16, 2022
The AI and QC specialists have joined to use AI and QC in order to discover biological pathways relevant to the treatment of triple-negative breast cancer.
Pharmacy Times
AUGUST 16, 2022
Investigators aimed to determine how individuals with and without concomitant NSP differ in characteristics and in their perception of treatment responses to analgesics.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Pharmacy Times
AUGUST 16, 2022
A new study warns that fluoroquinolone could increase the risk of altered mental status and hospitalizations for advanced chronic kidney disease patients, though it is rare.
Pharmaceutical Technology
AUGUST 16, 2022
Gilead Sciences has entered an agreement with Everest Medicines to acquire complete rights to develop and market Trodelvy (sacituzumab govitecan) in Greater China, Singapore, South Korea, Philippines, Vietnam, Thailand, Indonesia, Mongolia and Malaysia. According to the deal, Everest is entitled to receive an upfront payment of $280m from Gilead. Furthermore, Gilead will make potential payments of up to $175m to Everest on meeting certain regulatory and commercial milestones.
Pharmacy Times
AUGUST 16, 2022
The FDA has issued a rule that will grant millions of Americans access to OTC hearing aids in pharmacies or online without a prescription or medical exam required.
European Pharmaceutical Review
AUGUST 16, 2022
The Phase III RATIONALE 301 study evaluated the efficacy and safety of tislelizumab versus sorafenib as a first-line systemic treatment in participants with unresectable hepatocellular carcinoma. . Hepatocellular carcinoma, or HCC, is the sixth most common type of cancer worldwide. HCC accounted for more approximately 85 percent of the 900,000 new liver cancer cases in 2020, according to the Globocan 2020 database. .
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Pharmacy Times
AUGUST 16, 2022
High rates of HIV can decrease with community-based support.
The FDA Law Blog
AUGUST 16, 2022
By Douglas B. Farquhar — Those of us who work frequently on FDA inspections of drug and medical device manufacturing facilities have noticed an uptick in regular inspections after a dramatic falloff during the first two years of COVID. That impression was corroborated this week at the GMP by the Sea conference when Douglas Throckmorton, Deputy Director for Regulatory Programs at FDA’s Center for Drug Evaluation and Research, stated that domestic FDA inspections of facilities have been performed
Pharmacy Times
AUGUST 16, 2022
Guidelines provide information on the management and treatment of this common skin condition.
Digital Pharmacist
AUGUST 16, 2022
On August 9th, 2022, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the JYNNEOS vaccine. Here is what you need to know about the monkeypox vaccine emergency use authorization. . JYNNEOS Vaccine Authorization Details . This authorization allows healthcare providers to administer the vaccine by intradermal injection for high risk individuals that are 18 years of age or older.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Pharmacy Times
AUGUST 16, 2022
A potential public health benefit of 13-valent pneumococcal conjugate vaccine is the reduction of acute chest syndrome among children with sickle-cell disease.
European Pharmaceutical Review
AUGUST 16, 2022
The Queen’s Award for Enterprise is the UK’s highest accolade for business success and recognises the strength of Quay Pharma’s export sales, which, according to SGS, have comprised at least 55 percent of its business since 2010. The enterprise also noted that in the last three years its overseas sales had more than doubled. The International Trade category recognises those who have had a clear business strategy for entering new markets abroad, have overcome the challenges faced by exporte
Pharmacy Times
AUGUST 16, 2022
The Preventing Addiction Related Suicide module was found to better improve suicide knowledge, increase help-seeking behaviors, and reduce maladaptive attitudes compared with usual care for patients with substance use disorders.
Outsourcing Pharma
AUGUST 16, 2022
The National Institute for Health and Care Excellence is weighing the viability of PD Neurotechnologyâs PDMonitor system for Parkinsonâs disease patients.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Pharmacy Times
AUGUST 16, 2022
Specialty pharmacies are well positioned to address disparities that affect outcomes.
Pharmaceutical Commerce
AUGUST 16, 2022
Three of the authors of a new EY study exploring the evolution of industry supply chain strategies and the long-term implications for healthcare delivery across three major trade regions discuss the report’s key findings and share their predictions as we move into Q3.
Pharmacy Times
AUGUST 16, 2022
Both ibrutinib (Imbruvica) and venetoclax (Venclexta) carry an approved indication for use in chronic lymphocytic leukemia but do not often lead to complete remission, and therapy routinely continues indefinitely or until disease progression.
pharmaphorum
AUGUST 16, 2022
The UK’s Joint Committee on Vaccinations and Immunisations (JCVI) has said that Moderna’s bivalent COVID-19 vaccine should be used for the autumn booster campaign in adults. The new recommendations came hard on the heels of the authorisation of the new shot, which provides protection against the original strain of the virus and the Omicron variant, by the Medicines and Healthcare products Regulatory Agency (MHRA).
Pharmacy Times
AUGUST 16, 2022
The new proposal will have grave effects on the sustainability of community oncology practices.
Pharmaceutical Technology
AUGUST 16, 2022
In 2019, Daiichi Sankyo entered a global development and commercialisation agreement with AstraZeneca for Daiichi Sankyo’s lead antibody-drug conjugate (ADC), Enhertu (trastuzumab deruxtecan), in a deal worth $6.9bn. This was followed by a further deal for the global development and commercialisation of another ADC, datopotamab deruxtecan (DS-1062) in 2020, with a deal value of up to $6bn.
Pharmacy Times
AUGUST 16, 2022
ClearoGout aids in the prevention of gout attacks.
PharmExec
AUGUST 16, 2022
Wed, Aug 17, 2022 2:00 PM EDT Recent advances in both oncology drug development and novel digital technologies provide a ripe opportunity to enhance the clinical trial process. Join Colin Weller and Musaddiq Khan from Medable as they discuss the key considerations around these innovations.
Pharmacy Times
AUGUST 16, 2022
Febuxostat) Uloric is a xanthine oxidase inhibitor indicated for the chronic management of hyperuricemia in patients with gout.
Pharmaceutical Technology
AUGUST 16, 2022
Q32 Bio has signed a partnership and option agreement with Horizon Therapeutics for developing ADX-914 to treat autoimmune ailments. According to the deal, Horizon will provide the funding to develop the therapy until the conclusion of its two Phase II clinical trials. Furthermore, Q32 will oversee the conduct of all programme-linked works. Under the agreement, Horizon will hold an option for the acquisition of the ADX-914 programme, which is exercisable through a period after concluding the Pha
Pharmacy Times
AUGUST 16, 2022
With costs for blood and blood products continuing to rise, appropriate blood use by hospitals is more important than ever.
pharmaphorum
AUGUST 16, 2022
With fears of a recession and inflation running high, the boom period for digital health apps looks to be waning. In this article, Ben Hargreaves looks at how companies have reacted to an unfavourable economic climate and what that could mean for the long-term growth of the industry. The idea 12 months ago that the health and wellness app space could soon be facing a crisis would have seemed highly pessimistic.
Pharma Times
AUGUST 16, 2022
Researchers are invited to apply to receive DNA that has been synthesised using Evonetix’s platform
pharmaphorum
AUGUST 16, 2022
On the same day as it reported encouraging new data for its cancer drug Trodelvy, Gilead Sciences has agreed a deal to buy rights to the drug in Asia held by Chinese drugmaker Everest Medicines. The US company said it is paying $280 million upfront to acquire rights to the drug in Greater China, South Korea, Singapore, Indonesia, Philippines, Vietnam, Thailand, Malaysia and Mongolia, with another $175 million tied to the achievement of regulatory and commercial objectives in those territories.
Pharma Times
AUGUST 16, 2022
New therapy is aimed at patients with metastatic castration-resistant prostate cancer
Expert insights. Personalized for you.
264 
Let's personalize your content